GoldenGolden
CRISPR Therapeutics

CRISPR Therapeutics

A biopharmaceutical and gene editing company founded in 2013. CRISPR Therapeutics AG is based in Zug, Switzerland and CRISPR Therapeutics, Inc. is the U.S. subsidiary with R&D operations in Cambridge, Massachusetts and business offices in London, U.K.

CRISPR Therapeutics is a biopharmaceutical and synthetic biology company using genetic engineering to create medical therapies that is headquartered in Zug, Switzerland and was founded in 2013 by Chad Cowan, Craig Mello, Daniel Anderson, Emmanuelle Charpentier, Matthew Porteus, Rodger Novak, and Shaun Foy.

CRISPR Therapeutics is developing medicine for serious diseases using the CRISPR-Cas9 platform that co-founder Emmanuelle Charpentier and Jennifer Doudna co-developed and published together in Science in 2012 . Charpentier and Doudna were awarded the 2015 Breakthrough Prize in Life Sciences. Charpentier is one of the co-founders and is an advisor to CRISPR Therapeutics which was initially called Inception Genomics AG.

CRISPR Therapeutics’ lead product candidate, CTX001, targets sickle cell disease and beta-thalassemia. Cells are harvested from a patient, treated ex vivo with the CRISPR-Cas9-based therapeutic, and returned to the patient. A clinical trial for CTX001 began in December 2017. Other therapeutic developments include CTX101 and other CAR-T therapies to target cancer. CAR-T therapies are chimeric antigen receptor T cell therapies which are immune cells engineered to find and destroy cancer cells. Hemoglobinopathies and regenerative medicine are other areas they are working in.

Partners
Vertex Pharmaceuticals

CRISPR Therapeutics began separate collaborations with Vertex Pharmaceuticals and Bayer in 2015. The joint venture with Bayer has been named Casebia Therapeutics and focuses of blood disorders, blindness and congenital heart disease.

Funding
Series A

On April 20, 2015 CRISPR Therapeutics completed their series A funding round with $35 million in funding from SR One (lead investor), Celgene (lead investor), New Enterprise Associates, Versant Ventures, and Abingworth.

Series B

On June 24, 2016 CRISPR Therapeutics completed their series B funding round with $140 million in funding from New Leaf Venture Partners (lead investor), Franklin Templeton Investments (lead investor), Vertex Pharmaceuticals (lead investor), Bayer Global Investments (lead investor), Wellington Capital Management, Frank Templeton Investments, and Clough Capital Partners.

Timeline

June 2016
CRISPR Therapeutics raises a $38,000,000 series B round from Clough Capital Partners, Franklin Templeton Investments, New Leaf Venture Partners and Wellington Management.
April 2015
CRISPR Therapeutics raises a $35,000,000 series A round from Abingworth, Celgene, New Enterprise Associates, Sr One and Versant Ventures.
April 2015
CRISPR Therapeutics raises a $29,000,000 series B round from Celgene, New Enterprise Associates, Sr One, Versant Ventures and Vertex Pharmaceuticals.
April 2014
CRISPR Therapeutics raises a $25,000,000 series A round from Versant Ventures.
2013
CRISPR Therapeutics was founded by Chad Cowan, Craig Mello, Daniel Anderson, Emmanuelle Charpentier, Matthew Porteus, Rodger Novak and Shaun Foy.

Funding rounds

People

Name
Role
LinkedIn

Emmanuelle Chapentier

Co-Founder, Scientific Advisory Board

Michael Tomsicek

CFO

Rodger Novak

Co-Founder and President

Samarth Kulkarni

CEO

Shaun Foy

Co-Founder, former CFO

Further reading

Title
Author
Link
Type
Date

Documentaries, videos and podcasts

Title
Date
Link

Companies

Company
CEO
Location
Products/Services

News

Title
Author
Date
Publisher
Description
Kyle LaHucik
June 9, 2021
FierceBiotech
ViaCyte snagged $45 million in a new tranche of financing to expand on a 2018 series D worth $80 million. The money will fund the biotech's work on two midstage candidates for type 1 diabetes, and it comes just a day after the biotech said its chief scientific officer is leaving.
Brandon May
May 7, 2021
BioSpace
Biopharmaceutical company CRISPR Therapeutics has entered into a strategic research, development and commercialization partnership with cancer-focused Nkarta.
BioSpace
April 26, 2021
BioSpace
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) and CRISPR Therapeutics (Nasdaq: CRSP) today announced the European Medicines Agency (EMA) has granted Priority Medicines (PRIME) designation to CTX001, an investigational, autologous, ex vivo CRISPR/Cas9 gene-edited therapy for the treatment of transfusion-dependent beta thalassemia (TDT).
BioSpace
April 26, 2021
BioSpace
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) and CRISPR Therapeutics (Nasdaq: CRSP) today announced the European Medicines Agency (EMA) has granted Priority Medicines (PRIME) designation to CTX001, an investigational, autologous, ex vivo CRISPR/Cas9 gene-edited therapy for the treatment of transfusion-dependent beta thalassemia (TDT).
Andrew Dunn
April 22, 2021
Business Insider
The bestseller chronicles Jennifer Doudna's discovery of CRISPR and the vast potential of gene editing.
Annalee Armstrong
April 20, 2021
FierceBiotech
Vertex has boosted an agreement with CRISPR Therapeutics to $900 million upfront as the companies race to beat bluebird bio to the market with a new gene editing therapy for sickle cell disease and beta-thalassemia called CTX001.
Mark Terry
April 20, 2021
BioSpace
Under the terms of the expanded deal, Vertex will be responsible for 60% of the costs of developing, manufacturing and commercializing CTX001 with support from CRISPR Therapeutics, and will receive 60% of profits from global sales.
BioSpace
April 20, 2021
BioSpace
Under terms of amended agreement, Vertex to lead worldwide development, manufacturing and commercialization of CTX001
BioSpace
April 10, 2021
BioSpace
CRISPR Therapeutics, a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, announced preclinical data from the Company's allogeneic chimeric antigen receptor T cell program at the American Association for Cancer Research Annual Meeting 2021.
Andrew Dunn and Allison DeAngelis
January 15, 2021
Business Insider
Gene therapy biotechs were overshadowed and struggled, while a highly debated theory on treating Alzheimer's disease got a boost.
Megan Molteni
December 28, 2020
Wired
Between glimpses of a medical cure and winning science's shiniest prize, this proved to the gene-editing technology's biggest year yet.
Megan Molteni
December 28, 2020
Wired
Between glimpses of a medical cure and winning science's shiniest prize, this proved to the gene-editing technology's biggest year yet.
Steve Dent
December 7, 2020
Engadget
A breakthrough in CRISPR gene editing for patients with blood diseases shows the promise and problems with the new technology.
By MARION RENAULT
December 5, 2020
AP NEWS
Scientists are seeing promising early results from the first studies testing gene editing for painful, inherited blood disorders that plague millions worldwide.Doctors hope the one-time...
Krystle Vermes
November 23, 2020
BioSpace
Scientists in Israel have used the CRISPR Cas-9 gene editing system to destroy cancerous cells in mice without damaging other cells.
Krystle Vermes
November 23, 2020
BioSpace
Scientists in Israel have used the CRISPR Cas-9 gene editing system to destroy cancerous cells in mice without damaging other cells.
November 19, 2020
BioSpace
Vor Biopharma Promotes Tirtha Chakraborty to Chief Scientific Officer - read this article along with other careers information, tips and advice on BioSpace
Amirah Al Idrus
November 19, 2020
FierceBiotech
SR One has backed biotech companies for decades as GlaxoSmithKline's venture arm. Now, the firm is striking out on its own, having spun out from the British conglomerate and raised a whopping $500 million fund. The fund, SR One's first, will back "elite" biotechs on both sides of the Atlantic, working on new medicines to address treatment gaps.
Jacob Koshy
October 13, 2020
The Hindu
How is the tool different from other editing systems? Is there a possibility of the tool being misused?
Nick Paul
November 5, 2020
FierceBiotech
CRISPR Therapeutics and Vertex have presented updated data on their CRISPR/Cas9 gene-editing therapy in sickle cell disease and beta thalassemia, showing patients continue to benefit from the drug. Yet, hemoglobin levels fell in two of the seven patients in the latest update, raising early questions about the durability of CTX001.
SHOW MORE

References

Page 1 of 2
Golden logo
Text is available under the Creative Commons Attribution-ShareAlike 4.0; additional terms apply. By using this site, you agree to our Terms & Conditions.